Inari Medical (NARI) Stock Price, News & Analysis

Company Overview

Inari Medical (NASDAQ: NARI) is a commercial-stage medical device company dedicated to developing innovative therapies for the treatment of venous diseases. The company’s core focus lies in addressing the substantial unmet clinical needs of patients suffering from acute and chronic venous thromboembolic disorders, including pulmonary embolism (PE) and deep vein thrombosis (DVT). By pioneering minimally invasive mechanical thrombectomy technologies, Inari Medical aims to improve patient outcomes, reduce hospital stays and limit the need for thrombolytic drugs that carry bleeding risks.

Among its flagship products are the FlowTriever® System and the ClotTriever® System. The FlowTriever System is designed to rapidly extract large clots from pulmonary arteries without the use of thrombolytics, offering an alternative to catheter-directed thrombolysis in the management of PE. The ClotTriever System targets peripheral veins, enabling physicians to remove significant clot burden in a single session for patients with acute and chronic DVT. Both platforms leverage proprietary catheter and catheter-enhancement technologies to facilitate safe and efficient clot retrieval.

Since its founding in 2011 and initial public offering in 2018, Inari Medical has expanded its commercial footprint across the United States and into select international markets, including Europe, where it collaborates with distribution partners to reach a broader physician base. The company’s headquarters in Irvine, California serves as the hub for its research, development and manufacturing activities. With a commitment to clinical evidence generation, Inari Medical supports ongoing trials and real-world registries that aim to demonstrate long-term patient benefits and cost-effectiveness of its therapies.

Under the leadership of Chief Executive Officer Christopher Calhoun and a management team with extensive experience in cardiovascular and interventional medicine, Inari Medical continues to invest in product innovation and market expansion. The company’s strategic priorities include enhancing its product portfolio, reinforcing its direct and indirect sales channels, and fostering partnerships with healthcare providers to drive broader adoption of its thrombectomy technologies.

Key Stats

• Today's Range: $79.97 to $79.97
• 50-Day Range: $79.97 to $79.97
• 52-Week Range: $39.76 to $79.99
• Volume: N/A
• Average Volume: 1.44 million shs
• Market Capitalization: $4.68 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $69.22
• Consensus Rating: Hold

NARI Stock Analysis - Frequently Asked Questions

How have NARI shares performed this year?

Inari Medical's stock was trading at $51.05 on January 1st, 2025. Since then, NARI stock has increased by 56.7% and is now trading at $79.97.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.01 by $0.09. The company's quarterly revenue was up 22.5% compared to the same quarter last year.
Read the conference call transcript.

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an initial public offering (IPO) on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inari Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 2/28/2024
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NARI
• CIK: 1531048
• Web: www.inarimedical.com
• Phone: 877-923-4747
• Fax: N/A
• Employees: 800
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $69.22
• High Stock Price Target: $80.00
• Low Stock Price Target: $47.00
• Potential Upside/Downside: -13.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.64 million
• Net Margins: -13.68%
• Pretax Margin: -9.29%
• Return on Equity: -10.09%
• Return on Assets: -6.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $493.63 million
• Price / Sales: 9.48
• Cash Flow: $0.09 per share
• Price / Cash Flow: 906.95
• Book Value: $8.07 per share
• Price / Book: 9.91

Miscellaneous

• Outstanding Shares: 58,540,000
• Free Float: 52,338,000
• Market Cap: $4.68 billion
• Optionable: Optionable
• Beta: 1.02